Corbus Pharmaceuticals Advances with FDA Fast Track Designation

Corbus Pharmaceuticals ( (CRBP) ) has shared an update.

Corbus Pharmaceuticals has secured FDA Fast Track designation for its innovative drug CRB-701, aimed at treating relapsed or refractory metastatic cervical cancer. This promising next-generation antibody drug conjugate specifically targets Nectin-4 and is currently undergoing a Phase 1 clinical trial to assess its safety and efficacy. Investors eagerly anticipate initial results from the study in early 2025, highlighting a potential breakthrough in oncology treatment.

Learn more about CRBP stock on TipRanks’ Stock Analysis page.